Chakma Justin's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Nov 27, 2024
- Accession no.
- 0001415889-24-027843
- Filed
- Nov 27, 2024
- Trade date
- Nov 25-27, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.41M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chakma JustinCIK 0001951238 | Officer (Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 25, 2024 | Common Stock | SSaleDisposed | −32,814 | $14.00 | −$459,396 | 203,566 | Direct | |
| Nov 26, 2024 | Common Stock | SSaleDisposed | −42,186 | $14.05 | −$592,713.3 | 161,380 | Direct | |
| Nov 27, 2024 | Common Stock | SSaleDisposed | −25,000 | $14.39 | −$359,750 | 136,380 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.